478 related articles for article (PubMed ID: 11822346)
1. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
2. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
[TBL] [Abstract][Full Text] [Related]
3. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
5. Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital.
Lee M; Pao D; Hsu T; Sonderskov A
Can J Clin Pharmacol; 2004; 11(1):e17-27. PubMed ID: 15226523
[TBL] [Abstract][Full Text] [Related]
6. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
8. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
9. Economics of low-molecular weight heparins.
Rutschmann OT; Matchar DB
Am J Manag Care; 2000 Nov; 6(20 Suppl):S1054-65; quiz 1066-7. PubMed ID: 11484305
[TBL] [Abstract][Full Text] [Related]
10. An outpatient program to treat deep venous thrombosis with low-molecular-weight heparin.
Pearson SD; Blair R; Halpert A; Eddy E; Mckean S
Eff Clin Pract; 1999; 2(5):210-7. PubMed ID: 10623053
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.
Santamaría A; Juárez S; Reche A; Gómez-Outes A; Martínez-González J; Fontcuberta J;
Int J Clin Pract; 2006 May; 60(5):518-25. PubMed ID: 16700847
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study.
Goldstein JL; Larson LR; Yamashita BD; Fain JM; Schumock GT
Am J Gastroenterol; 2001 Aug; 96(8):2360-6. PubMed ID: 11513175
[TBL] [Abstract][Full Text] [Related]
13. The use of pharmacoeconomics in formulary development: can this improve the way deep vein thrombosis is treated?
White TJ
Am J Manag Care; 2001 Nov; 7(17 Suppl):S545-50; discussion S550-2. PubMed ID: 11732665
[TBL] [Abstract][Full Text] [Related]
14. Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery.
Nutescu EA; Shorr AF; Farrelly E; Horblyuk R; Happe LE; Franklin M
Ann Pharmacother; 2008 Sep; 42(9):1216-21. PubMed ID: 18611992
[TBL] [Abstract][Full Text] [Related]
15. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program.
Groce JB
Pharmacotherapy; 1998; 18(6 Pt 3):175S-180S. PubMed ID: 9853912
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
17. Expedited discharge in trauma patients requiring anticoagulation for deep venous thrombosis prophylaxis: the LEAP Program.
Bridges GG; Lee MD; Jenkins JK; Stephens MA; Croce MA; Fabian TC
J Trauma; 2003 Feb; 54(2):232-5. PubMed ID: 12579045
[TBL] [Abstract][Full Text] [Related]
18. Early discharge of patients with venous thromboembolism: implications regarding therapy.
Stein PD; Hull RD; Matta F; Yaekoub AY
Clin Appl Thromb Hemost; 2010 Apr; 16(2):141-5. PubMed ID: 19833629
[TBL] [Abstract][Full Text] [Related]
19. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
20. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
